Beam Therapeutics

company

About

Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$260M
Industries
Biotechnology,Genetics,Medical,Therapeutics
Founded date
Jan 1, 2017
Number Of Employee
501 - 1000
Operating Status
Active
Stock Symbol
nasdaq:BEAM
Legal Name
Beam Therapeutics, Inc.

Beam Therapeutics is a biotechnology company engaged in creating genetic medicines based on its base editing technology. It is pioneering the use of base editing, a potential new class of precision genetic medicines, with a vision of providing life-long cures to patients suffering from serious diseases. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the dna.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
5
$867M
Beam Therapeutics has raised a total of $867M in funding over 2 rounds. Their latest funding was raised on Jan 19, 2021 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 19, 2021 Post-IPO Equity $260M 5 — — Detail
Feb 11, 2020 Post-IPO Equity $207M — — — Detail
Feb 5, 2020 IPO $178M — — — Detail
Mar 6, 2019 Series B $135M 8 — — Detail
May 14, 2018 Series A $87M 3 ARCH Venture Partners
F-Prime Capital
— Detail

Employee Profiles

Number of Employee Profiles
25
Beam Therapeutics has 25 current employee profiles, including Executive Adam Fung
Executive
Executive
Executive
Executive
Executive

Acquisition

Beam Therapeutics has acquired 1 organizations. Their most recent acquisition was Guide Therapeutics on Feb 23, 2021. They acquired Guide Therapeutics for 0.

Date Company Name
Industry Acquisition Type Price
Biotechnology acquisition — Detail